Skip to content

US · RXST · MEDICAL - DEVICES

RxSight, Inc. (RXST) intrinsic value and stock valuation

$4.47as of 2026-11-21 · Mkt cap 260.38M

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

RxSight, Inc. DCF and intrinsic value

InvestorsCraft values RXST with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from RXST’s statements →

RxSight, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Devices Aliso Viejo, CA 92656 rxsight.com

How the business is doing

Fiscal 2019–2025, USD

Revenue
$134.5M+55.7% 5y CAGRd
20192025
Net income
-$-38.94M
20192025
Free cash flow
-$-19.34M
20192025
Total equity
$275.7M
20192025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2019–2025, USD
20252024202320222021
Revenue$134.5M$139.9M$89.1M$49M$22.6M
Operating income-$-48.19M-$-36.86M-$-50.09M-$-63.32M-$-52.79M
Net income-$-38.94M-$-27.45M-$-48.61M-$-66.76M-$-48.69M
EPSd-$-945.6K-$-706.2K-$-1.41M-$-2.41M-$-1.78M
Operating cash flow-$-15.51M-$-16.95M-$-41.59M-$-58.85M-$-44.71M
Capital expenditure-$-3.83M-$-5.44M-$-4.81M-$-2.39M-$-1.94M
Free cash flow-$-19.34M-$-22.39M-$-46.41M-$-61.24M-$-46.65M
Total assets$311.8M$318.6M$182.6M$150.2M$192.7M
Total debt$11M$12.3M$3.01M$45M$44.9M
Net debt-$-8.91M-$-4.41M-$-6.68M$33.2M$20.6M
Total equity$275.7M$281.2M$160.4M$89.9M$138.2M
Cash and short-term investments$228.1M$237.2M$127.2M$105.8M$159.3M
Income statement
20252024202320222021
Revenue$134.5M$139.9M$89.1M$49M$22.6M
Cost of revenue$31.5M$41M$35.3M$27.7M$18.1M
Gross profit$103M$98.9M$53.8M$21.3M$4.52M
Research and development expenses$38.6M$34.4M$29.1M$26M$24.5M
Selling, general and administrative expenses$112.7M$101.4M$74.8M$58.7M$32.8M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$151.2M$135.8M$103.9M$84.7M$57.3M
Cost and expenses$182.7M$176.8M$139.2M$112.3M$75.4M
Interest income$2.51M$9.47M$6.57M$1.52M$50K
Interest expense$40K$20K$3.31M$4.95M$3.68M
Depreciation and amortization$0.00$3.62M$4.24M$4.02M$3.99M
Ebitda-$-38.84M-$-23.76M-$-41.04M-$-57.78M-$-41.01M
Operating income-$-48.19M-$-36.86M-$-50.09M-$-63.32M-$-52.79M
Total other income/expenses, net$9.31M$9.45M$1.5M-$-3.43M$4.11M
Income before tax-$-38.88M-$-27.41M-$-48.59M-$-66.75M-$-48.68M
Income tax expense$70K$50K$20K$10K$10K
Net income-$-38.94M-$-27.45M-$-48.61M-$-66.76M-$-48.69M
Weighted average shares outstanding$41.2M$38.9M$34.5M$27.7M$27.4M
Weighted average diluted shares outstanding$41.2M$38.9M$34.5M$27.7M$27.4M
Balance sheet
20252024202320222021
Cash and short-term investments$228.1M$237.2M$127.2M$105.8M$159.3M
Net receivables$23.4M$30.1M$20.3M$11M$4.86M
Inventory$31.6M$22M$17.4M$14.8M$8.03M
Total current assets$287.5M$293.8M$168.4M$134.6M$176.3M
Property, plant and equipment, net$23M$23.6M$13.3M$14.1M$15.5M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$750K$710K$0.00$0.00
Total non-current assets$24.4M$24.7M$14.1M$15.6M$16.4M
Total assets$311.8M$318.6M$182.6M$150.2M$192.7M
Accounts payable$5.3M$4.54M$3.86M$2.6M$1.69M
Short-term debt$1.16M$970K$1.8M$1.97M$1.53M
Deferred revenue$3.6M$3.11M$2.04M$1.35M$620K
Total current liabilities$26.3M$25.9M$20.9M$17.2M$11.1M
Long-term debt$9.88M$11.3M$1.21M$43M$43.4M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$9.88M$11.5M$1.28M$43M$43.4M
Capital lease obligations$1.16M$11.3M$3.01M$4.83M$5.17M
Total liabilities$36.1M$37.3M$22.2M$60.3M$54.5M
Common stock$40K$40K$40K$30K$30K
Retained earnings-$-661.04M-$-622.1M-$-594.64M-$-546.03M-$-479.28M
Accumulated other comprehensive income (loss)$50K$170K-$-10K-$-100K-$-20K
Total equity$275.7M$281.2M$160.4M$89.9M$138.2M
Total investments$208.2M$220.5M$118.2M$94M$135M
Total debt$11M$12.3M$3.01M$45M$44.9M
Net debt-$-8.91M-$-4.41M-$-6.68M$33.2M$20.6M
Cash flow statement
20252024202320222021
Net income-$-38.94M-$-27.45M-$-48.61M-$-66.76M-$-48.69M
Depreciation and amortization$3.27M$3.62M$4.24M$4.02M$3.99M
Stock-based compensation$31.6M$24.6M$15.8M$11.4M$7.58M
Change in working capital-$-4.89M-$-9.21M-$-9.07M-$-7.41M-$-2.68M
Accounts receivable$6.66M-$-9.8M-$-9.32M-$-6.09M-$-2M
Inventory-$-11.48M-$-4.99M-$-2.75M-$-7.55M-$-2.11M
Accounts payable$630K$950K$1.25M$640K$560K
Net cash provided by operating activities-$-15.51M-$-16.95M-$-41.59M-$-58.85M-$-44.71M
Investments in property, plant and equipment-$-3.83M-$-5.44M-$-4.81M-$-2.39M-$-1.94M
Acquisitions, net$0.00$0.00$17.3M-$-42.34M$80M
Net cash used for investing activities$16.9M-$-99.31M-$-22.13M$40M-$-81.91M
Common stock issued$3.95M$128.9M$106M$7.83M$121.1M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$1.86M$123.3M$61.5M$6.33M$137.3M
Net change in cash$3.24M$7.05M-$-2.19M-$-12.58M$10.7M
Cash at end of period$20M$17.5M$10.4M$12.6M$25.2M
Operating cash flow-$-15.51M-$-16.95M-$-41.59M-$-58.85M-$-44.71M
Capital expenditure-$-3.83M-$-5.44M-$-4.81M-$-2.39M-$-1.94M
Free cash flow-$-19.34M-$-22.39M-$-46.41M-$-61.24M-$-46.65M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About RxSight, Inc.

        As a medical technology enterprise, RxSight, Inc. (which operated as Calhoun Vision, Inc. until its rebranding in February 2017) specializes in the innovation, manufacturing, and distribution of light-adjustable intraocular lenses (LALs). These advanced lenses are specifically designed for use in cataract surgery, serving patients in both domestic and international markets. The cornerstone of the company's offerings is the RxSight system, a sophisticated solution that enables ophthalmologists to precisely tailor and enhance a patient's visual acuity following cataract removal. An integral part of this system is the RxSight light delivery device, an in-office instrument. This device emits UV light in a carefully controlled pattern to modify the LAL, thereby ensuring optimal visual correction after the surgical procedure. RxSight's primary clientele consists of eye surgeons specializing in cataract treatments. The company was founded in 1997 and its corporate headquarters are situated in Aliso Viejo, California.

        CEO
        Aziz Mottiwala
        Employees
        461
        Beta
        1.15

        Explore

        Frequently asked questions

        What is the intrinsic value of RxSight, Inc. (RXST)?

        RxSight, Inc. (RXST) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is RXST undervalued?

        RXST trades at a price of $4.47 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.